In a cell model carrying a mutation in the GRN (Progranulin gene), the regulatory effect of PSAP was able to restore PGRN levels, suggesting that PSAP is a novel regulator of PGRN levels and oligomerization, and a potential target for treating frontotemporal dementia (FTD) and other neurodegenerative diseases [137]. The gene discussed is GRN; the disease is frontotemporal dementia.